Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) - Total Liabilities

Latest as of December 2024: TL303.09 Million TRY ≈ $6.79 Million USD

Based on the latest financial reports, Nasmed Ozel Saglik Hizmetleri Ticaret AS (EGEPO) has total liabilities worth TL303.09 Million TRY (≈ $6.79 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Nasmed Ozel Saglik Hizmetleri Ticaret AS - Total Liabilities Trend (2019–2024)

This chart illustrates how Nasmed Ozel Saglik Hizmetleri Ticaret AS's total liabilities have evolved over time, based on quarterly financial data. See EGEPO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Nasmed Ozel Saglik Hizmetleri Ticaret AS Competitors by Total Liabilities

The table below lists competitors of Nasmed Ozel Saglik Hizmetleri Ticaret AS ranked by their total liabilities.

Company Country Total Liabilities
Neto M.E Holdings Ltd
TA:NTO
Israel ILA1.21 Billion
Omega Oil & Gas Ltd
AU:OMA
Australia AU$2.83 Million
Suprema Inc
KQ:236200
Korea ₩28.79 Billion
LF Capital Acquisition Corp. II Units
NASDAQ:LFACU
USA $5.08 Million
Panca Budi Idaman Tbk PT
JK:PBID
Indonesia Rp591.61 Billion
The Lovesac Company
NASDAQ:LOVE
USA $295.44 Million
Tanco Holdings Bhd
KLSE:2429
Malaysia RM158.74 Million
Tigo Energy Inc.
NASDAQ:TYGO
USA $34.01 Million

Liability Composition Analysis (2019–2024)

This chart breaks down Nasmed Ozel Saglik Hizmetleri Ticaret AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Nasmed Ozel Saglik Hizmetleri Ticaret AS.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.64 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.22 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.18 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nasmed Ozel Saglik Hizmetleri Ticaret AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nasmed Ozel Saglik Hizmetleri Ticaret AS (2019–2024)

The table below shows the annual total liabilities of Nasmed Ozel Saglik Hizmetleri Ticaret AS from 2019 to 2024.

Year Total Liabilities Change
2024-12-31 TL303.09 Million
≈ $6.79 Million
-26.08%
2023-12-31 TL410.01 Million
≈ $9.18 Million
+128.87%
2022-12-31 TL179.14 Million
≈ $4.01 Million
+83.27%
2021-12-31 TL97.75 Million
≈ $2.19 Million
+10.05%
2020-12-31 TL88.82 Million
≈ $1.99 Million
+31.57%
2019-12-31 TL67.51 Million
≈ $1.51 Million
--

About Nasmed Ozel Saglik Hizmetleri Ticaret AS

IS:EGEPO Turkey Medical Care Facilities
Market Cap
$211.88 Million
TL9.46 Billion TRY
Market Cap Rank
#16419 Global
#199 in Turkey
Share Price
TL18.92
Change (1 day)
-0.58%
52-Week Range
TL6.93 - TL19.83
All Time High
TL32.10
About

Nasmed Özel Saglik Hizmetleri Ticaret Anonim Sirketi provides healthcare services in Turkey. The company's medical units include oral and dental health; anesthesiology and reanimation; nutrition and diet; brain and nerve surgery; childhood diseases; dermatology; endocrinology and metabolic diseases; infectious diseases and clinical microbiology; aesthetic, plastic, and reconstructive surgery; hom… Read more